Trial · NCT04032704
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704, Phase 2, Terminated, Seagen Inc.; results first posted 2025-03-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. Trials, record NCT04032704. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04032704
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- NCT number
- NCT04032704
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 205 participants, actual
- Lead sponsor
- Seagen Inc.
- Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
- Interventions
- ladiratuzumab vedotin, pembrolizumab
- First posted
- 2019-07-25
- Last updated
- 2025-03-10
- Results first posted
- 2025-03-10
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 8.3 months) | Confirmed ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as more than or equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not have at least 2 post-baseline response assessment (initial response and confirmation scan) were counted as non-responders. |
| Primary | Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 34.7 months for 1.25 mg/kg and 5.7 months for 1 mg/kg dose level) | Confirmed ORR was defined as the percentage of participants with a confirmed CR or PR per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not have at least 2 post-baseline response assessment (initial response and confirmation scan) were counted as non-responders. |
| Primary | Part B: Confirmed Prostate-Specific Antigen (PSA) Response Rate as Determined by Investigator According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria, for Prostate Cancer | From the first dose of study treatment up to the date of last response assessment (maximum up to 13.5 months) | Confirmed PSA response rate was defined as the percentage of participants with a reduction from baseline PSA level of at least 50%, measured twice \>= 3 weeks apart. PSA progression was defined as per PCWG3 criteria- a) if a participant presented first a decline from baseline, progression was defined as the first PSA increase that was \>=25% and \>=2 nanograms per milliliter (ng/mL) above the nadir, and which was confirmed by a consecutive second value \>=3 weeks later that fulfilled the same criteria (that is, a confirmed rising trend); b) if a participant did not present a decline from baseline, progression was defined as the first PSA increase that was \>=25% and \>=2 ng/mL increased from baseline beyond 12 weeks. |
| Secondary | Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs and >= Grade 3 TEAE | From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months) | An adverse event (AE) was any untoward medical occurrence in a participant/ clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. AEs included both SAEs ad all non-SAEs. TEAEs were defined as newly occurring (not present at baseline)/worsening after first dose of study treatment. TESAEs were any untoward medical occurrence at any dose that: suspected to cause death; life-threatening; required hospitalization; persistent/significant disability/incapacity \& may cause congenital anomaly/birth defect. Treatment related TEAEs were related to study treatment and relatedness was judged by investigator. TEAEs were graded according to National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03 (grade 1= mild, grade 2= moderate, grade 3= severe and grade 4= life-threatening). |
| Secondary | Part B: Number of Participants With TEAEs, TESAEs, Treatment Related TEAEs and >= Grade 3 TEAE | From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months) | An AE was any untoward medical occurrence in a participant, or a clinical investigational participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. AEs included both SAEs ad all non-SAEs. TEAEs were defined as newly occurring (not present at baseline) or worsening after first dose of study treatment. TESAEs were any untoward medical occurrence at any dose that: suspected to cause death; life-threatening; required hospitalization; persistent or significant disability or incapacity and may cause congenital anomaly or birth defect. Treatment related TEAEs were related to study treatment and relatedness was judged by investigator. TEAEs were graded according to NCI-CTCAE v4.03 (grade 1= mild, grade 2= moderate, grade 3= severe and grade 4= life-threatening). |
| Secondary | Part A: Confirmed Investigator Determined Disease Control Rate (DCR) According to RECIST v1.1 | From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 4.1 months) | DCR was defined as percentage of participants who achieved confirmed and unconfirmed CR or PR per RECIST v1.1 or met stable disease (SD) criteria at least once after start of study treatment at minimum interval of 5 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as \>= 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference smallest sum diameters while on study. PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions was also considered progression. |
| Secondary | Part B: Confirmed Investigator Determined DCR According to RECIST v1.1 | From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 5.5 months for 1.25 mg/kg and 1.5 months for 1 mg/kg dose level) | DCR was defined as percentage of participants who achieved confirmed and unconfirmed CR or PR per RECIST v1.1 or met SD criteria at least once after start of study treatment at a minimum interval of 5 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 centimeter (cm). Appearance of one or more new lesions was also considered progression. |
| Secondary | Part A: Confirmed Investigator Determined Duration of Response (DOR) According to RECIST v1.1 | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 5.7 months) | DOR:time from 1st documentation of OR(confirmed CR/PR per RECIST Version 1.1) to 1st documentation of PD/death due to any cause,whichever occurred first.CR:disappearance of all target lesions.Any pathological lymph nodes must have reduction in short axis to \<10 mm.PR:\>=30 % decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Participants do not have PD and are still on study at time of analysis/are removed from study prior to documentation of PD were censored at last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at last disease assessment prior to start of new treatment.PD:at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study.In addition to relative increase of 20%, sum must demonstrate absolute increase of 0.5 cm.Appearance of one/more new lesions was considered progression. Kaplan-Meier method was used. |
| Secondary | Part B: Confirmed Investigator Determined DOR According to RECIST v1.1 | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 32.0 months for 1.25 mg/kg and 4.2 months for 1 mg/kg dose level) | DOR:time from 1st documentation of OR(confirmed CR/PR per RECIST Version 1.1) to 1st documentation of PD/death due to any cause,whichever occurred first.CR:disappearance of all target lesions.Any pathological lymph nodes must have reduction in short axis to \<10 mm.PR:\>=30 % decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Participants do not have PD and are still on study at time of analysis/are removed from study prior to documentation of PD were censored at last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at last disease assessment prior to start of new treatment.PD:at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study.In addition to relative increase of 20%, sum must demonstrate absolute increase of 0.5 cm.Appearance of one/more new lesions was considered progression. Kaplan-Meier method was used. |
| Secondary | Part B: Confirmed Investigator Determined PSA-DOR, for Prostate Cancer | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 3 months) | PSA-DOR was defined as the time from the first documentation of PSA response (subsequently confirmed at least 3 weeks apart) to the first documentation of PSA progression or death due to any cause, whichever occurred first. Confirmed PSA response rate was defined as the percentage of participants with a reduction from baseline PSA level of at least 50%, measured twice \>= 3 weeks apart. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD was censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. The confidence interval (CI) was calculated using the complementary log-log transformation method. |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 8.3 months) | The full analysis set (FAS) included all participants who received any amount of study drug. | Percentage of participants | NUMBER |
| PRIMARY | Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 34.7 months for 1.25 mg/kg and 5.7 months for 1 mg/kg dose level) | The FAS included all participants who received any amount of study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| PRIMARY | Part B: Confirmed Prostate-Specific Antigen (PSA) Response Rate as Determined by Investigator According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria, for Prostate Cancer | From the first dose of study treatment up to the date of last response assessment (maximum up to 13.5 months) | The FAS included all participants who received any amount of study drug. As prespecified in protocol, this outcome measure was planned to be analyzed only in the Part B: Cohort 7, LV 1.25 mg/kg arm. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs and >= Grade 3 TEAE | From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months) | The safety analysis set included all participants who received any amount of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part B: Number of Participants With TEAEs, TESAEs, Treatment Related TEAEs and >= Grade 3 TEAE | From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months) | The safety analysis set included all participants who received any amount of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Part A: Confirmed Investigator Determined Disease Control Rate (DCR) According to RECIST v1.1 | From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 4.1 months) | The FAS included all participants who received any amount of study drug. | Percentage of participants | NUMBER |
| SECONDARY | Part B: Confirmed Investigator Determined DCR According to RECIST v1.1 | From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 5.5 months for 1.25 mg/kg and 1.5 months for 1 mg/kg dose level) | The FAS included all participants who received any amount of study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Part A: Confirmed Investigator Determined Duration of Response (DOR) According to RECIST v1.1 | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 5.7 months) | The FAS included all participants who received any amount of study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. No participant had CR or PR in Part A: Cohort 2, LV 2.5 mg/kg arm. | Months | MEDIAN |
| SECONDARY | Part B: Confirmed Investigator Determined DOR According to RECIST v1.1 | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 32.0 months for 1.25 mg/kg and 4.2 months for 1 mg/kg dose level) | The FAS included all participants who received any amount of study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. No participant had CR or PR in Part B: Cohort 4, LV 1.25 mg/kg arm, Part B: Cohort 7, LV 1.25 mg/kg arm, Part B: Cohort 1, LV 1.0 mg/kg arm, Part B: Cohort 3, LV 1.0 mg/kg arm and Part B: Cohort 4, LV 1.0 mg/kg arm. | Months | MEDIAN |
| SECONDARY | Part B: Confirmed Investigator Determined PSA-DOR, for Prostate Cancer | From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 3 months) | The FAS included all participants who received any amount of study drug. As prespecified in protocol, this outcome measure was planned to be analyzed only in the Part B: Cohort 7, LV 1.25 mg/kg arm. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. | Months | MEDIAN |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 outcomesResults by group332
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 1, LV 2.5 mg/kg | 10 | 95% Confidence Interval 0.3 to 44.5 | Percentage of participants | |
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 2, LV 2.5 mg/kg | 0 | 95% Confidence Interval 0.0 to 84.2 | Percentage of participants | |
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 3, LV 2.5 mg/kg | 8 | 95% Confidence Interval 0.2 to 36.0 | Percentage of participants | |
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 4, LV 2.5 mg/kg | 14 | 95% Confidence Interval 0.4 to 57.9 | Percentage of participants | |
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 5, LV 2.5 mg/kg | 20 | 95% Confidence Interval 0.5 to 71.6 | Percentage of participants | |
| Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Part A: Cohort 6, LV 2.5 mg/kg | 8 | 95% Confidence Interval 0.2 to 38.5 | Percentage of participants | |
| Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | Part B: Cohort 1, LV 1.25 mg/kg | 6 | 95% Confidence Interval 0.2 to 30.2 | Percentage of participants | |
| Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | Part B: Cohort 2, LV 1.25 mg/kg | 13 | 95% Confidence Interval 1.6 to 38.3 | Percentage of participants | |
| Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | Part B: Cohort 3, LV 1.25 mg/kg | 11 | 95% Confidence Interval 1.3 to 33.1 | Percentage of participants | |
| Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1 | Part B: Cohort 4, LV 1.25 mg/kg | 0 | 95% Confidence Interval 0.0 to 23.2 | Percentage of participants |
1 to 10 of 332Source ClinicalTrials.gov
See all 332 results by groupParticipant flow108
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A | STARTED | Part A: Cohort 1, LV 2.5 mg/kg | 10 | |
| Part A | STARTED | Part A: Cohort 2, LV 2.5 mg/kg | 2 | |
| Part A | STARTED | Part A: Cohort 3, LV 2.5 mg/kg | 13 | |
| Part A | STARTED | Part A: Cohort 4, LV 2.5 mg/kg | 7 | |
| Part A | STARTED | Part A: Cohort 5, LV 2.5 mg/kg | 5 | |
| Part A | STARTED | Part A: Cohort 6, LV 2.5 mg/kg | 12 | |
| Part A | STARTED | Part B: Cohort 1, LV 1.25 mg/kg | 0 | |
| Part A | STARTED | Part B: Cohort 2, LV 1.25 mg/kg | 0 | |
| Part A | STARTED | Part B: Cohort 3, LV 1.25 mg/kg | 0 | |
| Part A | STARTED | Part B: Cohort 4, LV 1.25 mg/kg | 0 |
1 to 10 of 108Source ClinicalTrials.gov
See all 108 participant flowAdverse events5,976
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 1, LV 2.5 mg/kg | 0 | 10 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 2, LV 2.5 mg/kg | 0 | 2 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 3, LV 2.5 mg/kg | 2 | 13 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 4, LV 2.5 mg/kg | 1 | 7 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 5, LV 2.5 mg/kg | 1 | 5 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Part A: Cohort 6, LV 2.5 mg/kg | 2 | 12 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Cohort 1, LV 1.25 mg/kg | 2 | 16 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Cohort 2, LV 1.25 mg/kg | 0 | 16 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Cohort 3, LV 1.25 mg/kg | 2 | 19 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | Part B: Cohort 4, LV 1.25 mg/kg | 2 | 14 | 2 |
1 to 10 of 5,976Source ClinicalTrials.gov
See all 5,976 adverse eventsAdverse event totals54
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Part A: Cohort 1, LV 2.5 mg/kg | 9 | 10 |
| Total, all-cause mortality | Part A: Cohort 2, LV 2.5 mg/kg | 2 | 2 |
| Total, all-cause mortality | Part A: Cohort 3, LV 2.5 mg/kg | 10 | 13 |
| Total, all-cause mortality | Part A: Cohort 4, LV 2.5 mg/kg | 7 | 7 |
| Total, all-cause mortality | Part A: Cohort 5, LV 2.5 mg/kg | 4 | 5 |
| Total, all-cause mortality | Part A: Cohort 6, LV 2.5 mg/kg | 5 | 12 |
| Total, all-cause mortality | Part B: Cohort 1, LV 1.25 mg/kg | 13 | 16 |
| Total, all-cause mortality | Part B: Cohort 2, LV 1.25 mg/kg | 13 | 16 |
| Total, all-cause mortality | Part B: Cohort 3, LV 1.25 mg/kg | 14 | 19 |
| Total, all-cause mortality | Part B: Cohort 4, LV 1.25 mg/kg | 12 | 14 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04032704
GET https://conductscience.org/api/trials/v1/NCT04032704/registered?page=2